Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Blood
; 141(6): 579-591, 2023 02 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36130300
3.
Genetic justification of COVID-19 patient outcomes using DERGA, a novel data ensemble refinement greedy algorithm.
J Cell Mol Med
; 28(4): e18105, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38339761
4.
Thrombotic and bleeding complications in patients with AL amyloidosis.
Br J Haematol
; 204(5): 1816-1824, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38321638
5.
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
N Engl J Med
; 385(1): 46-58, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34192431
6.
How I treat relapsed multiple myeloma.
Blood
; 139(19): 2904-2917, 2022 05 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35007326
7.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA.
Blood
; 139(6): 835-844, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289038
8.
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
Blood
; 139(4): 492-501, 2022 01 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-34269818
9.
Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I/II study.
Haematologica
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38356458
10.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385280
11.
Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis.
Haematologica
; 2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299578
12.
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide-exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
Am J Hematol
; 99(3): 396-407, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38298023
13.
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group.
Lancet Oncol
; 24(7): e293-e311, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414019
14.
Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indices.
Clin Immunol
; 246: 109218, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36586431
15.
Outcomes of patients with light chain (AL) amyloidosis after failure of daratumumab-based therapy.
Br J Haematol
; 203(3): 411-415, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37580907
16.
Outcomes for patients with systemic light chain amyloidosis and Mayo stage 3B disease.
Hematol Oncol
; 41(4): 725-732, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-36974438
17.
Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Br J Clin Pharmacol
; 89(5): 1640-1655, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-36484341
18.
Plain Language Summary of the iNNOVATE study: ibrutinib plus rituximab is well-tolerated and effective in people with Waldenström's macroglobulinemia.
Future Oncol
; 19(5): 345-353, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36815271
19.
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study.
Lancet Oncol
; 23(3): 416-427, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-35151415
20.
Immune response and adverse events after vaccination against SARS-CoV-2 in adult patients with transfusion-dependent thalassaemia.
Br J Haematol
; 197(5): 576-579, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35286720